8-K current report · filed Aug 17, 2026

DocGo Inc. (DCGO) 8-K Current Report: August 17, 2026

Item 1.01Item 2.02Item EX-99.1Item EX-99.2DCGO overview

Short answer

DocGo Inc. (DCGO) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Proposed acquisition of Hicuity through merger, positioning it as a wholly owned Ambulnz subsidiary.

DocGo Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Proposed acquisition of Hicuity through merger, positioning it as a wholly owned Ambulnz subsidiary
  • Consideration equals 2.0% of DocGo fully diluted shares, plus up to 3.5% in performance-based earnout shares
  • Earnout shares vest only if DocGo reaches a specified market capitalization threshold; otherwise forfeited
  • Ambulnz assumes Hicuity indebtedness and receives authority to fund operations pending closing
  • Perceptive committed up to $50 million new senior secured term loans, alongside $52 million existing term loans

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 earnings covered quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the reported financial results
  • Management scheduled earnings conference call for August 17, 2026 at 5:00 p.m. Eastern Time
  • Adjusted gross margin, adjusted EBITDA, and adjusted operating expenses to be discussed as non-GAAP measures
  • Exhibit 99.2 provides reconciliations to comparable GAAP measures; materials furnished, not filed

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $73.4M, down from $80.4M as migrant programs ended; core revenue excluding migrants rose 19% YoY
  • Net loss widened to $18.0M; adjusted EBITDA remained negative at $6.3M, highlighting ongoing profitability risk
  • Cash and investments declined to $48.1M, including unrestricted cash of $25.2M, increasing reliance on financing
  • Hicuity acquisition adds $65M trailing revenue and $4.5M adjusted EBITDA, funded through assumed $52M debt and equity issuance
  • 2026 adjusted EBITDA guidance worsened to negative $17M-$22M from negative $5M-$10M, despite narrowed revenue guidance of $305M-$310M

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $73.4M, down from $80.4M, while adjusted EBITDA loss widened to $6.3M from $6.1M
  • Six-month revenue $149.0M versus $176.5M, with adjusted EBITDA loss worsening to $16.5M from $10.0M
  • Consolidated adjusted gross margin fell to 30.5% from 31.6% in Q2 and 31.1% from 31.9% year-to-date
  • Mobile Health revenue declined to $21.4M from $30.8M, with adjusted gross margin dropping to 27.0% from 32.5%
  • Transportation revenue rose to $52.0M from $49.6M, while adjusted gross margin improved to 32.0% from 31.1%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other DocGo Inc. 8-K filings

Get the next DCGO 8-K as it lands

Follow DCGO for push alerts, or ask the research agent what this filing means.